IVEV.F Stock Overview
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Inventiva S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €3.64 |
| 52 Week High | €4.06 |
| 52 Week Low | €3.64 |
| Beta | 0.96 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 51.67% |
Recent News & Updates
Recent updates
Shareholder Returns
| IVEV.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 1.0% | 1.2% |
| 1Y | n/a | 0.7% | 24.9% |
Return vs Industry: Insufficient data to determine how IVEV.F performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how IVEV.F performed against the US Market.
Price Volatility
| IVEV.F volatility | |
|---|---|
| IVEV.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: IVEV.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine IVEV.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 122 | Frederic Cren | www.inventivapharma.com |
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.
Inventiva S.A. Fundamentals Summary
| IVEV.F fundamental statistics | |
|---|---|
| Market cap | US$168.10m |
| Earnings (TTM) | -US$118.18m |
| Revenue (TTM) | US$24.79m |
6.8x
P/S Ratio-1.4x
P/E RatioIs IVEV.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IVEV.F income statement (TTM) | |
|---|---|
| Revenue | €23.16m |
| Cost of Revenue | €1.02m |
| Gross Profit | €22.15m |
| Other Expenses | €132.57m |
| Earnings | -€110.43m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Sep 25, 2024
| Earnings per share (EPS) | -2.12 |
| Gross Margin | 95.61% |
| Net Profit Margin | -476.73% |
| Debt/Equity Ratio | -148.3% |
How did IVEV.F perform over the long term?
See historical performance and comparison